The global Personal Genome Testing Market is forecast to be appraised at USD 4,468 Million by 2032, up from USD 1,545.5 Million in 2022, advancing at a CAGR of 10.1% during the forecast period.
| Attributes | Details |
|---|---|
| Personal Genome Testing Market Size (2022) | USD 1,545.5 Million |
| Personal Genome Testing Market Size (2032) | USD 4,468 Million |
| Personal Genome Testing Market CAGR (2022 to 2032) | 10.1% |
The advancements in the field of genetic testing, along with its wide usage in pharmacogenomics and toxicogenomic, drives the demands for personal genome testing. Increasing deployment of paternity testing, maternity testing, and prenatal testing promotes personal genome testing market growth.
The increased and developing awareness among healthcare professionals regarding the efficacy of these diagnostics owing to strong testing volumes ordered and managed by non-geneticists surges the adoption of personal genome testing.
Lifestyle-based and nutrition-based genetic tests are widely available for aiding diet and lifestyle plans among consumers, increasing demand for personal genome testing. The accuracy and reliable technology of genetic testing, and the growing awareness about its benefits, propels the personal genome testing market share.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
With the expansion of DTC genetic tests' application areas, the market share for personal genome testing increases. The market for personal genome testing is being expanded by businesses that provide DTC tests for use in continuing research, sports, nutrition, and other areas.
The range of services offered by genetic testing, such as data security, identification of ancestors, race and nature of family, increasing its usage in clinical practices, surges demand for personal genome testing.
The low cost value of genome testing across clinics, ranging from USD 99 to USD 2000, drives the demand for personal genome testing. Rising prevalence of genetic diseases related to genotype, phenotype, or mutation, and its need for detection and prevention propels the personal genome testing market growth.
The ability to detect genetic abnormalities in the early gestation period of 8 to 10 weeks surges the demand for personal genome testing. Growing R&D activities, along with government initiatives in the field, escalates the adoption of personal genome testing.
Increasing awareness and discoveries in the field of genetic testing, as well as the option to determine the sex of a fetus, broadens the personal genome testing market share. Descriptive information regarding analytical validity and clinical validity of the tests offered by the service provide, increases the demand for personal genome testing.
The requirement for identification and addressing of specific needs, personalized direct-to-consumer genetic tests, escalates the personal genome testing market size. Favorable reimbursement policies and increasing coverage for preventative genetic testing elevate the personal genome testing market share.
Due to the shortage of trained professionals, end users face significant issues in analyzing genomic data, hindering the personal genome testing market growth. Rigid regulatory requirements for product approvals are expected to hamper the demand for personal genome testing.
The personal genome testing market size is further obstructed owing to standardization concerns of genetic testing-based diagnostics.
Furthermore, the unavailability of doctors and genetic counselors, along with closing of test-running laboratories leading to disruption, limitation and challenges during the pandemic, hampered the adoption of personal genome testing.
Scepticism and criticism regarding genetic testing from healthcare professionals, owing to lack of evidence, thwarts the personal genome testing market share.
The desire for personal genome testing is curbed by the loss of discretion and control over customers' genetic material, as well as the risk that testing procedures could lead to a third party accessing clients' DNA information.
Principal Consultant
Unexplored emerging markets in developing economies and a high number of customers opting for online genetic testing are anticipated to promote the global personal genome testing market growth.
Moreover, the adoption of personal genome testing increases owing to the growth in the personalized medicine market, especially among the pharmaceutical companies. The shift of focus from clinical science to bioinformatics, and the increasing popularity of these techniques, increases the demand for personal genome testing.
Increased efficiency, accuracy, and new innovations and techniques further propel the demand for personal genome testing.
North America holds the leading position in the personal genome testing market share, with a revenue of 37.3%.
This is owing to the rise in cases of genetic diseases and an increasing demand for technologically advanced medical equipment for treatment. The availability of a substantial number of key players dealing with genetic tests in this region surges the demand for personal genome testing.
High awareness about at-home testing among the U.S. population promotes the global personal genome testing market growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Europe has the second leading personal genome testing market share, with a revenue share of 26%.
The rising demand for technologically advanced medical equipment for treatment in this region promotes personal genome testing market growth.
The presence of key players, as well as new players entering the market causing competition, secures the expansion of the personal genome testing market size.
Due to rising knowledge of the advantages of genetic testing, the personal genome testing market share is predicted to increase in Asia-Pacific. Personal genome testing is becoming more popular as a result of growing awareness of numerous genetic illnesses and an increase in their prevalence in this area.
Rapid development of healthcare infrastructures across Asian countries further promotes market growth.
Several market players, through research and development activities, are coming up with innovative strategies to refine genetic testing in clinics. They are also implementing schemes to protect the privacy of their clients’ DNA information.
Emerging players such as 3x4 Genetics, 3billion, CircaGene, Bione, Athletic Genetix, etc. are offering various services such as DNA-based fitness programs, genetic testing for rare diseases, personalized genetic test platforms, microbiome testing, genetic testing for athletes, etc.
Some of the key market participants in the personal genome testing market are 23andMe Inc., Navigenics, deCODEme, Color Genomics Inc., Personal Genome Diagnostics Inc., Counsyl, Inc., Quest Diagnostics, Gene By Gene Ltd., Laboratory Corporation of America Holdings, Thermo Fisher Scientific, QIAGEN N.V., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., BGI, MYRIAD GENETICS, INC. (MYRIAD RBM, INC.), Eurofins Scientific, CSL Ltd., Abbott Laboratories, Invitae Corporation, Ambry Genetics, BioReference, Progenity Inc., and others are coming up with new innovations to perfect the extraction of genetic material.
Rising cases of chronic diseases are increasing the adoption of personal genome testing. This is attributed to the growth of key players in the market, which is increasing competitiveness in the market, surging the demand for personal genome testing.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 10.1% from 2022 to 2032 |
| Base year for estimation | 2021 |
| Historical data | 2015 to 2020 |
| Forecast period | 2022 to 2032 |
| Quantitative units | Revenue in USD million and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
| Segments covered | Type, Application, and Region. |
| Regional scope | North America; Western Europe; Eastern Europe; Middle East; Africa; ASEAN; South Asia; Rest of Asia; Australia and New Zealand |
| Country scope | USA, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa |
| Key companies profiled | 23andMe Inc.; Navigenics; deCODEme; Color Genomics Inc.; Personal Genome Diagnostics Inc.; Counsyl, Inc.; Quest Diagnostics; Gene By Gene Ltd.; Laboratory Corporation of America Holdings; Thermo Fisher Scientific; QIAGEN N.V.; Agilent Technologies, Inc.; F. Hoffmann-La Roche Ltd.; Bio-Rad Laboratories Inc.; BGI; MYRIAD GENETICS, INC. (MYRIAD RBM, INC.); Eurofins Scientific; CSL Ltd.; Abbott Laboratories; Invitae Corporation; Ambry Genetics; BioReference; Progenity Inc.; Burning Rock Biotech Ltd.; Celera Group; PerkinElmer Inc.; Quest Diagnostics Inc.; ELITech Group; Roche Diagnostics Corp.; Applied Biosystems Inc.; Roche Molecular Diagnostics Inc.; Transgenomic Inc.; Color Genomics; EasyDNA; Family Tree DNA; Full Genome Corporation Inc.; Helix OpCo LLC; Karmagenes SA; Living DNA Ltd.; MyHeritage; 24 Genetics; The SkinDNA Company Pty Ltd; DNA Forensics Laboratory Pvt. Ltd. |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
Ans. Personal genome testing is likely to register a CAGR of 10.1% during the forecast period.
North America is the leading personal genome testing market, with a revenue share of 37.3%.
By 2032, the market is likely to grow to a valuation of USD 4,468 Million.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Personal Genome Testing Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 5. Global Personal Genome Testing Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application 5.1. Neurological Disorders 5.2. Oncology 5.3. Metabolic Disorders 5.4. Autoimmune Disorders 5.5. Others 6. Global Personal Genome Testing Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product Type 6.1. Targeted Testing 6.2. Non-Targeted Testing 6.3. Multi-Targeted Testing 7. Global Personal Genome Testing Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. MEA 8. North America Personal Genome Testing Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9. Latin America Personal Genome Testing Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10. Europe Personal Genome Testing Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11. Asia Pacific Personal Genome Testing Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12. MEA Personal Genome Testing Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13. Key Countries Personal Genome Testing Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. 23andMe, Inc. 15.2. Navigenics 15.3. deCODEme 15.4. Color Genomics, Inc 15.5. Personal Genome Diagnostics, Inc. 15.6. Counsyl, Inc. 15.7. Quest Diagnostics 15.8. Gene By Gene, Ltd. 15.9. Laboratory Corporation of America® Holdings 15.10. mapmygenome.in 15.11. Positive Bioscience, Inc 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Personal Genome Testing Market
